Entera Bio Ltd
Entera Bio Ltd (ENTX) Covered Calls
As of September 15, 2026, ENTX has 1 covered call opportunities in the coming three months. Return ranges from 43.4 to 43.4% until expiration. Annualized return ranges from 510.5 to 510.5%. The nearest expiration is October 16, 2026. Maximum potential profit is $124.
Read more
Running ENTX covered calls helps you generate consistent income from Entera Bio Ltd's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Entera Bio Ltd involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ENTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ENTX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ENTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Entera Bio Ltd covered call is worth writing.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Income-focused investors, long-term ENTX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ENTX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Entera Bio Ltd covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile11.90% Subdued
- Market cap (M$)497
- 52 weeks high-31.90%
- 52 weeks low214.29%
- Analyst recommendationStrong Buy
1.00 - Target price$9.00
214.69% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-13
- P/E—
- Future P/E—
- EPS (ttm)-0.35
- EPS growth next 5 years—
As of September 15, 2026
| 2026-10-16 | 31 | 4.00 | 39.86 | 0.10 | 1.35 | 124.00 | 43.36 | 510.49 | -3.50 | +0.54 | 195 | 1.25 |
As of September 15, 2026
Sell covered calls with the data behind you
Find the best ENTX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→